News
The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback